Apremilast for the treatment of Behcet’s syndrome

References

• Behçet H. Uber rezidivierende, aphthose, dürch ein Virus verursachte Geshwure am Munde, am Auge und an den Genitalien [in German]. Dematologische Wochenschrift. 1937;36:1152–1157.
   Google Scholar
• Yurdakul S, Hamuryudan V, Fresko I, et al. Behçet’s syndrome. In: Hochberg MC, Silman AJ, Smolen YS, et al., editors. Rheumatology. 4 Philadelphia (PA): Mosby Elsevier; 2008. p. 1561–1565.
   Google Scholar
• Emmi G, Silvestri E, Squatrito D, et al. Behçet’s syndrome pathophysiology and potential therapeutic targets. Intern Emerg Med. 2014 Apr;9(3):257–265.
   Google Scholar
• Yazici Y, Yurdakul S, Yazici H. Behcet’s syndrome. Curr Rheumatol Rep. 2010;12:429–435.
   Google Scholar
• Vitale A, Rigante D, Lopalco G, et al. New therapeutic solutions for Behçet’s syndrome. Expert Opin Investig Drugs. 2016 Jul;25(7):827–840.
   Google Scholar
• Perez-Aso M, Montesinos MC, Mediero A, et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015;17(1):249.
   Google Scholar
• Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10:1503–1519.
   Google Scholar
• McCann FE, Palfreeman AC, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of TNF-alpha from human rheumatoid arthritis synovial cells and ameliorates experimental arthritis. Arthritis Res Ther. 2010;12:1–11.
   Google Scholar
• Giembycz MA. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs. 2000;59:193–212.
   Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159:842–855.
   Google Scholar
• Otezla (apremilast) [package insert]. Summit (NJ): Celgene Corporation; 2014.
   Google Scholar
• Haber SL, Hamilton S, Bank M, et al. A novel drug for treatment of psoriasis and psoriatic arthritis. Ann Pharmacother. 2016 Apr;50(4):282–290. Epub 2016 Jan 18. DOI:10.1177/1060028015627467
   Google Scholar
• Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behçet’s syndrome – a phase 2, placebo-controlled study. N Engl J Med. 2015 Apr 16; 372(16):1510–1518.
   Google Scholar
• Bhakta BB, Brennan P, James TE, et al. Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38(8):728–733.
   Google Scholar
• Forbess C, Swearingen C, Yazici Y. Behçet’s syndrome activity score (BSAS): a new disease activity assessment tool, composed of patient-driven measures only, is strongly correlated with the Behçet’s Disease Current Activity Form (BDCAF) (abstract). Arthritis Rheum. 2008;58(Suppl):S854.
   Google Scholar
• Gilworth G, Chamberlain MA, Bhakta B, et al. Development of the BD-QoL: a quality of life measure specific to Behcet’s disease. J Rheumatol. 2004;31(5):931–937.
   Google Scholar
• Yazici Y, Bernstein H, Poon J, et al. Apremilast for the treatment of Behcet’s syndrome: routine care, real world experience. Clin Exp Rheumatol. 2016;34(6Suppl.102):185.
   Google Scholar
• Buyuktas D, Hatemi G, Yuksel-Findikoglu S, et al. Fatigue is correlated with disease activity but not with the type of organ involvement in Behçet’s syndrome: a comparative clinical survey. Clin Exp Rheumatol. 2015;33(6 Suppl 94):S107–12.
   Google Scholar
• Bozcan S, Ozguler Y, Saygin C, et al. Predictors of quality of life in Behçet’s syndrome. Ann Rheum Dis. 2015;74(Suppl2):526.
   Google Scholar
• Aktulga E, Altaç M, Müftüoglu A, et al. A double blind study of colchicine in Behçet’s disease. Haematologica. 1980;65(3):399–402.
   Google Scholar
• Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum. 2001;44(11):2686–2692.
   Google Scholar
• Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19(5):542–549.
   Google Scholar
• Hatemi G, Silman A, Bang D; EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67(12):1656–1662.
   Google Scholar
• Hatemi G, Silman A, Bang D, et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis. 2009;68(10):1528–1534.
   Google Scholar
• Kötter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Semin Arthritis Rheum. 2004;33(5):311–319.
   Google Scholar
• Alibaz-Oner F, Mumcu G, Kubilay Z, et al. Unmet need in Behcet’s disease: most patients in routine follow-up continue to have oral ulcers. Clin Rheumatol. 2014;33(12):1773–1776.
   Google Scholar
• Gordon JN. CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease. J Crohns Colitis. 2009;3:175–182.
   Google Scholar